Forma Therapeutics, Holdings Inc.
If you purchased Forma Therapeutics, Holdings Inc. securities and would like to join the action, please click "Join This Action" below.
FMTX STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF FORMA THERAPEUTICS, HOLDINGS INC. IS FAIR TO SHAREHOLDERS
September 1, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Forma Therapeutics, Holdings Inc. (NASDAQ: FMTX) to Novo Nordisk for $20.00 per share in cash is fair to Forma shareholders.
The investigation concerns whether Forma and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Forma shareholders; (2) determine whether Novo Nordisk is underpaying for Forma; and (3) disclose all material information necessary for Forma shareholders to adequately assess and value the merger consideration. On behalf of Forma shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.